Indefinite Delivery Contract SPE2DX15D9221

This federal contract IDV was awarded by the Defense Logistics Agency (DLA) Medical Supply Chain division to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $499,999,999 single-award Indefinite Delivery Contract (IDC) under the SPE2DB program enables the DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical items, including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables. This IDC supports the recurring medical supply needs of military healthcare facilities and veterans' medical centers nationwide, with a period of performance through November 2026.

The specific delivery orders awarded under this IDC cover a diverse portfolio of pharmaceutical products such as Xolair, Trikafta, Keytruda, Botox, Nucala, Donnatal Elixir, YF-VAX, Glycopyrrolate, Adenosine, Naloxone, Intralipid, Cyclogyl, and Tamiflu. These firm fixed-price awards do not have any set-aside designations, allowing DMS Pharmaceutical Group to leverage its status as a woman-owned small business to secure direct federal contracts across multiple medical product categories. Through this IDC and other prime vendor agreements, DMS Pharmaceutical Group serves as a crucial supplier in the federal pharmaceutical supply chain, providing critical medications and medical supplies to support the healthcare needs of the U.S. military and veterans.